West Pharmaceutical Services, Inc.
WST
$230.11
$6.382.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.89B | 2.88B | 2.88B | 2.93B | 2.95B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.89B | 2.88B | 2.88B | 2.93B | 2.95B |
| Cost of Revenue | 1.89B | 1.87B | 1.85B | 1.84B | 1.82B |
| Gross Profit | 998.50M | 1.00B | 1.03B | 1.09B | 1.13B |
| SG&A Expenses | 334.90M | 342.30M | 349.40M | 354.80M | 354.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 900.00K | 1.90M | 900.00K | 1.20M | 1.30M |
| Total Operating Expenses | 2.30B | 2.29B | 2.27B | 2.26B | 2.24B |
| Operating Income | 593.60M | 589.80M | 606.40M | 664.00M | 706.20M |
| Income Before Tax | 600.20M | 604.80M | 627.10M | 683.80M | 715.70M |
| Income Tax Expenses | 107.50M | 105.20M | 102.20M | 115.10M | 122.30M |
| Earnings from Continuing Operations | 492.70 | 499.60 | 524.90 | 568.70 | 593.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 492.70M | 499.60M | 524.90M | 568.70M | 593.40M |
| EBIT | 593.60M | 589.80M | 606.40M | 664.00M | 706.20M |
| EBITDA | 749.00M | 740.40M | 752.50M | 805.30M | 843.50M |
| EPS Basic | 6.75 | 6.81 | 7.11 | 7.68 | 7.99 |
| Normalized Basic EPS | 5.27 | 5.20 | 5.35 | 5.83 | 6.17 |
| EPS Diluted | 6.69 | 6.73 | 7.02 | 7.57 | 7.87 |
| Normalized Diluted EPS | 5.22 | 5.15 | 5.29 | 5.76 | 6.08 |
| Average Basic Shares Outstanding | 292.00M | 293.40M | 294.90M | 296.20M | 297.20M |
| Average Diluted Shares Outstanding | 294.70M | 296.40M | 298.30M | 300.00M | 301.40M |
| Dividend Per Share | 0.81 | 0.80 | 0.79 | 0.78 | 0.77 |
| Payout Ratio | 12.00% | 11.73% | 11.07% | 10.13% | 9.61% |
